Skip to main content

Articles By MedPage Today

lupus malar SLE

Cachexia Common in Lupus

By MedPage Today
12 August 2020

Cachexia is an underappreciated complication of systemic lupus erythematosus, researchers reported.

Read Article
Lknee.OA_.jpg

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

By MedPage Today
05 August 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported. Among patients enrolled in CANTOS, the pooled incidence rate for total hip replacement/total knee replacement was 0.31 events per 100 person-years for those receiving the monoclonal antibody every 3 months for up to 5 years compared with 0.54 per 100 for those given placebo, according to Paul M. Ridker, MD, of Harvard Medical School in Boston, and colleagues.

Read Article
obese.waist_.jpg

For TNF Response in RA, Weight Matters

By MedPage Today
22 July 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined. Compared with patients with normal weight, patients in obesity class II, whose body mass index (BMI) was 35 to 39.9, had a hazard ratio for shorter drug survival (i.e., the drug's effectiveness, safety, and tolerability) of 1.28 (95% CI 1.06-1.54), while those in obesity class III, whose BMI exceeded 40, had a hazard ratio of 1.67 (95% CI 1.29-2.18), according to Sytske Anne Bergstra, PhD, of Leiden University Medical Center in the Netherlands, and colleagues.

Read Article
EKG

HCQ May Help Prevent Fetal Heart Block

By MedPage Today
16 July 2020

Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.

Read Article
RA.hands

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

By MedPage Today
14 July 2020

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article
ACR

ACR Outlines Best Practices for Kids With MIS-C

By MedPage Today
25 June 2020

Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).

Read Article
patient.safety_0.jpg

Adverse Events With Rheum Biologics Rise With Age

By MedPage Today
23 June 2020

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.

Read Article
renal.genes__4.jpg

Voclosporin Beats Standard of Care in Lupus Nephritis

By MedPage Today
17 June 2020

The high potency calcineurin inhibitor voclosporin plus standard of care was superior to standard of care alone in a phase III study of lupus nephritis known as AURORA.

Read Article
cardiac2.jpg

Atherosclerotic Events on the Decline in SLE

By MedPage Today
15 June 2020

The prevalence of atherosclerotic vascular events among patients with systemic lupus erythematosus (SLE) today is considerably lower than in the past, analysis of multicenter data found. Among patients enrolled in an inception cohort from 1999 to 2017, only 3.6% of patients had an atherosclerotic vascular event, at a rate of 4.6 per 1,000 patient-years, according to Murray B. Urowitz, MD, of the University of Toronto in Canada, and colleagues.

Read Article
ICU

Methotrexate May Enhance Pegloticase Response in Gout

By MedPage Today
15 June 2020

For patients with gout exacerbations while on pegloticase (Krystexxa), adding methotrexate may help reduce uric acid levels, researchers suggested at the European League Against Rheumatism (EULAR) virtual meeting. In a small open-label study of 14 patients experiencing acute gout attacks, use of the pegloticase/methotrexate combination reduced uric acid levels to near undetectable levels in 11 patients, reported John Botson, MD, medical director of Orthopedic Physicians Alaska in Anchorage. He noted that this was far below the 5 mg/dL level recognized as the threshold for development of inflammation that causes gout attacks.

Read Article
×